This brand name is authorized in Estonia, Lithuania
The drug SYNTOSTIGMIN contains one active pharmaceutical ingredient (API):
|
1
Neostigmine
UNII 005SYP50G5 - NEOSTIGMINE BROMIDE
|
|
Neostigmine inhibits cholinesterase activity and prolongs and intensifies the muscarinic and nicotinic effects of acetylcholine. The anticholinesterase actions of neostigmine are reversible. It is used mainly for its action on skeletal muscle and less frequently to increase the activity of smooth muscle. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N07AA01 | Neostigmine | N Nervous system → N07 Other nervous system drugs → N07A Parasympathomimetics → N07AA Anticholinesterases |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EE | Ravimiamet | Identifier(s): 1832004 |
| Country: LT | Valstybinฤ vaistลณ kontrolฤs tarnyba | Identifier(s): 1015489 |
ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
